Insights

Gathering insights about Xenon…

Similar companies to Xenon

Xenon Tech Stack

Media & News

Xenon to Present at Upcoming Investor Conferences
VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences. Stifel 2025 Healthcare ConferenceThursday, November 13, 2025 at 3:20 PM ET Webcast link here Jefferies Global Healthcare Conference in London onWednesday, November 19, 2025 at 11:30 AM GMT/6:30 AM ET Webcast link here Details about company presentations, webcasts, and other events can be found on the Investors section of Xenon's website.
Nov 06, 2025 | www.globenewswire.com
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports narrower-than-expected Q3 loss as the biotech advances multiple late-stage studies of azetukalner across epilepsy and mood disorders.
Nov 04, 2025 | www.zacks.com
Xenon Pharmaceuticals Inc. (XENE) Q3 2025 Earnings Call Transcript
Xenon Pharmaceuticals Inc. ( XENE ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Colleen Alabiso Ian Mortimer - President, CEO, Principal Accounting Officer & Director Christopher Kenney - Chief Medical Officer Thomas Kelly - Chief Financial Officer Darren Cline - Chief Commercial Officer and Member of Executive Team Conference Call Participants Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Johoon Kim - RBC Capital Markets, Research Division Charles Moore - Robert W. Baird & Co. Incorporated, Research Division Dina Ramadane - BofA Securities, Research Division Joseph Thome - TD Cowen, Research Division Brian Balchin - Jefferies LLC, Research Division Presentation Operator Good day, everyone, and thank you for standing by.
Nov 04, 2025 | seekingalpha.com
Xenon Reports Third Quarter 2025 Financial Results & Business Update
– Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit – Phase 1 Nav1.7 & Kv7 studies underway – Tucker Kelly appointed as Chief Financial Officer, bringing extensive strategic commercial finance experience in anticipation of the azetukalner launch – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today reported financial results for the third quarter ended September 30, 2025 and provided a business update. “We are entering an important, catalyst-rich period for Xenon.
Nov 03, 2025 | www.globenewswire.com
Xenon to Report Q3 2025 Financial Results on November 3, 2025
VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, November 3, 2025. Conference Call/Webcast Information: Date: Monday, November 3, 2025 Time: 4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast: Pre-register here Dial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID: 3971394 A live webcast of the company presentation will be available on the Investors section of Xenon's website and posted for replay following the event.
Oct 27, 2025 | www.globenewswire.com
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience
Oct 16, 2025 | www.globenewswire.com
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia and BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 77,750 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of October 2, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Oct 07, 2025 | www.globenewswire.com

Xenon's Email Address Formats

Xenon uses at least 1 format(s):

Xenon Email Formats	Example	Percentage
First@xenonmktg.com	John@xenonmktg.com	50%
First@xenonmktg.com	John@xenonmktg.com	50%

Frequently Asked Questions

What is Xenon's stock symbol?

Xenon is a publicly traded company; the company's stock symbol is XENE.

What is Xenon's official website and social media links?

Xenon's official website is xenonmktg.com and has social profiles on LinkedIn.

What is Xenon's SIC code NAICS code?

Xenon's SIC code is 8742 - Management Consulting Services NAICS code is 541613 - Marketing Consulting Services.

How many employees does Xenon have currently?

As of May 2025, Xenon has approximately 43 employees across 5 continents, including EuropeAsiaNorth America. Key team members include Owner & Commercial Translator: J. A. F.President: D. S.Managing Partner - Process & Environmental Analytics Division: M. A.. Explore Xenon's employee directory with LeadIQ.

What industry does Xenon belong to?

Xenon operates in the Advertising Services industry.

What is Xenon's email format?

Xenon's email format typically follows the pattern of First@xenonmktg.com. Find more Xenon email formats with LeadIQ.

Xenon

Advertising Services11-50 Employees

Learn about working at Xenon. Join LinkedIn today for free. See who you know at Xenon, leverage your professional network, and get hired.

Company Overview

Website: xenonmktg.com
SIC Code: 8742 - Management Consulting Services
Stock Symbol: XENE
NAICS Code: 541613 - Marketing Consulting Services
Employees: 11-50

Media & News

Funding & Financials

$500M$1B
Xenon's revenue is estimated to be in the range of $500M$1B

Funding & Financials

$500M$1B
Xenon's revenue is estimated to be in the range of $500M$1B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Xenon

Vertical Doors

Seibon Carbon

Extreme Dimensions

Xenon Tech Stack

Media & News

Xenon to Present at Upcoming Investor Conferences

Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus

Xenon Pharmaceuticals Inc. (XENE) Q3 2025 Earnings Call Transcript

Xenon Reports Third Quarter 2025 Financial Results & Business Update

Xenon to Report Q3 2025 Financial Results on November 3, 2025

Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon's Email Address Formats

Frequently Asked Questions

What is Xenon's stock symbol?

What is Xenon's official website and social media links?

What is Xenon's SIC code NAICS code?

How many employees does Xenon have currently?

What industry does Xenon belong to?

What is Xenon's email format?

Xenon

Company Overview

Media & News

Xenon to Present at Upcoming Investor Conferences

Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus

Xenon Pharmaceuticals Inc. (XENE) Q3 2025 Earnings Call Transcript

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?